Earlier today, Provention Bio (PRVB) announced it will host a Q3 2022 quarterly report on November 3 (details here). While it’s always helpful to get an update from management, all that matters at this point is whether or not the FDA grants approval for teplizumab on or before the November 17 PDUFA date.
As you know, I’ve long contested that it’s simply a matter of when, not if Provention secures approval. Now that we’re only weeks away from finding out if that time has (finally) arrived, you’ll find a full rundown on the company and the opportunity below…
This content is reserved for subscribers